Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& V9 s# ^' K5 W
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 " d% Y* Y, q+ i2 X" Y% e- w
+ Author Affiliations
0 c4 i8 Q0 V6 y1 |- z9 O7 |5 |2 I1 g3 e4 l0 {2 C
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan / |/ C2 D% Q: Y% k+ k! o
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
* F' S# `6 {7 {2 {% O. l3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 n A; t+ k6 i$ w3 F+ A) Q p# p
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 0 U7 o1 k8 ?' k; c2 _1 I
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan , G$ s. a1 i6 `
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : p+ q8 Z# [% |. T9 _) I* t1 E9 R
7Kinki University School of Medicine, Osaka 589-8511, Japan
: c& N, p/ h# j( d, s7 T2 Y8Izumi Municipal Hospital, Osaka 594-0071, Japan 1 S. }0 n- H9 K5 n# E- G
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
Z' w( a2 ]7 y' K2 m4 |0 z/ {, JCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 7 |, L0 C+ M8 d9 E' w
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. $ k$ ]9 o3 t- i% Z8 N/ g
: B% @* ~, y) V' g% y
|